Nitrogen N-13 clinical trials
How each study uses nitrogen N-13 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2006 | 1 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Point Biomedical (6)
Studies
Open first, then newest update. How each study uses nitrogen N-13 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007CompletedPhase 3Point BiomedicalNCT00595673Written as PB127 for injectable suspension
- Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery DiseaseCompletedPhase 3Point BiomedicalNCT00595244Written as PB127 for injectable suspension
- Familiarization and Safety Study of PB127 Ultrasound Contrast AgentCompletedPhase 2/3Point BiomedicalNCT00594698Written as PB127 for injectable suspension
- Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery DiseaseTerminatedPhase 3Point BiomedicalNCT00584896Written as PB127 for Injectable Suspension
- Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound SystemsTerminatedPhase 2Point BiomedicalNCT00487903Written as PB127 for Injectable Suspension
- Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery DiseaseCompletedPhase 2Point BiomedicalNCT00584818Written as PB127 for Injectable Suspension